Monitoring and Management of the Patient with Stargardt Disease

References

• Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101(1):25–30. doi:10.1136/bjophthalmol-2016-30882327491360
   PubMed Web of Science ®Google Scholar
• Lewis RA, Shroyer NF, Singh N, et al. Genotype/Phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR, in Stargardt disease. Am J Hum Genet. 1999;64(2):422–434. doi:10.1086/3022519973280
   PubMed Web of Science ®Google Scholar
• Yi J, Li S, Jia X, et al. Evaluation of the ELOVL4, PRPH2 and ABCA4 genes in patients with Stargardt macular degeneration. Mol Med Rep. 2012;6(5):1045–1049. doi:10.3892/mmr.2012.106322948568
   PubMed Web of Science ®Google Scholar
• Fishman GA, Stone EM, Grover S, Derlacki DJ, Haines HL, Hockey RR. Variation of clinical expression in patients with Stargardt dystrophy and sequence variations in the ABCR gene. Arch Ophthalmol. 1999;117(4):504–510. doi:10.1001/archopht.117.4.50410206579
   PubMedGoogle Scholar
• Strauss RW, Ho A, Munoz B, et al. The natural history of the progression of atrophy secondary to stargardt disease (ProgStar) studies: design and baseline characteristics: progStar report no. 1. Ophthalmology. 2016;123(4):817–828. doi:10.1016/j.ophtha.2015.12.00926786511
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Triolo G, et al. Morpho-functional correlation of fundus autofluorescence in Stargardt disease. Br J Ophthalmol. 2015;99(10):1354–1359. doi:10.1136/bjophthalmol-2014-30623725837607
   PubMed Web of Science ®Google Scholar
• Parodi MB, Cicinelli MV, Iacono P, Bolognesi G, Bandello F. Multimodal imaging of foveal cavitation in retinal dystrophies. Graefes Arch Clin Exp Ophthalmol. 2017;255(2):271–279. doi:10.1007/s00417-016-3450-727491512
   PubMed Web of Science ®Google Scholar
• Battaglia Parodi M, Cicinelli MV, Rabiolo A, Pierro L, Bolognesi G, Bandello F. Vascular abnormalities in patients with Stargardt disease assessed with optical coherence tomography angiography. Br J Ophthalmol. 2017;101(6):780–785. doi:10.1136/bjophthalmol-2016-30886927628426
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Toto L, Borrelli E, et al. Optical coherence tomography angiography findings in Stargardt disease. PLoS One. 2017;12(2):e0170343. doi:10.1371/journal.pone.017034328151966
   PubMed Web of Science ®Google Scholar
• Guduru A, Lupidi M, Gupta A, Jalali S, Chhablani J. Comparative analysis of autofluorescence and OCT angiography in Stargardt disease. Br J Ophthalmol. 2018;102(9):1204–1207. doi:10.1136/bjophthalmol-2017-31100029074493
   PubMed Web of Science ®Google Scholar
• Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW Jr., Lam BL. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018;18(10):1049–1059. doi:10.1080/14712598.2018.151348630129371
   PubMed Web of Science ®Google Scholar
• Strauss RW, Kong X, Ho A, et al. Progression of stargardt disease as determined by fundus autofluorescence over a 12-month period: progStar report no. 11. JAMA OPHTHALMOL. 2019;137:1134. doi:10.1001/jamaophthalmol.2019.2885
   Web of Science ®Google Scholar
• Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol. 2010;703:105–125.20711710
   PubMed Web of Science ®Google Scholar
• Lenis TL, Hu J, Ng SY, et al. Expression of ABCA4 in the retinal pigment epithelium and its implications for Stargardt macular degeneration. Proc Natl Acad Sci U S A. 2018;115(47):E11120–E11127. doi:10.1073/pnas.180251911530397118
   PubMed Web of Science ®Google Scholar
• Kim SR, Jang YP, Jockusch S, Fishkin NE, Turro NJ, Sparrow JR. The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. Proc Natl Acad Sci U S A. 2007;104(49):19273–19278. doi:10.1073/pnas.070871410418048333
   PubMed Web of Science ®Google Scholar
• Radu RA, Yuan Q, Hu J, et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci. 2008;49(9):3821–3829. doi:10.1167/iovs.07-147018515570
   PubMed Web of Science ®Google Scholar
• Klevering BJ, Deutman AF, Maugeri A, Cremers FP, Hoyng CB. The spectrum of retinal phenotypes caused by mutations in the ABCA4 gene. Graefes Arch Clin Exp Ophthalmol. 2005;243(2):90–100. doi:10.1007/s00417-004-1079-415614537
   PubMed Web of Science ®Google Scholar
• Klevering BJ, Blankenagel A, Maugeri A, Cremers FP, Hoyng CB, Rohrschneider K. Phenotypic spectrum of autosomal recessive cone-rod dystrophies caused by mutations in the ABCA4 (ABCR) gene. Invest Ophthalmol Vis Sci. 2002;43(6):1980–1985.12037008
   PubMed Web of Science ®Google Scholar
• Cornelis SS, Bax NM, Zernant J, et al. In silico functional meta-analysis of 5,962 ABCA4 variants in 3,928 retinal dystrophy cases. Hum Mutat. 2017;38(4):400–408. doi:10.1002/humu.2017.38.issue-428044389
   PubMed Web of Science ®Google Scholar
• Salles MV, Motta FL, Martin R, et al. Variants in the ABCA4 gene in a Brazilian population with Stargardt disease. Mol Vis. 2018;24:546–559.30093795
   PubMed Web of Science ®Google Scholar
• Riveiro-Alvarez R, Lopez-Martinez MA, Zernant J, et al. Outcome of ABCA4 disease-associated alleles in autosomal recessive retinal dystrophies: retrospective analysis in 420 Spanish families. Ophthalmology. 2013;120(11):2332–2337. doi:10.1016/j.ophtha.2013.04.00223755871
   PubMed Web of Science ®Google Scholar
• Nassisi M, Mohand-Said S, Dhaenens CM, et al. Expanding the mutation spectrum in ABCA4: sixty novel disease causing variants and their associated phenotype in a large French Stargardt cohort. Int J Mol Sci. 2018;19:8. doi:10.3390/ijms19082196
   Web of Science ®Google Scholar
• Schulz HL, Grassmann F, Kellner U, et al. Mutation spectrum of the ABCA4 gene in 335 Stargardt disease patients from a multicenter german cohort-impact of selected deep intronic variants and common SNPs. Invest Ophthalmol Vis Sci. 2017;58(1):394–403. doi:10.1167/iovs.16-1993628118664
   PubMed Web of Science ®Google Scholar
• Di Iorio V, Orrico A, Esposito G, et al. Association between genotype and disease progression in italian stargardt patients: a retrospective natural history study. Retina. 2019;39(7):1399–1409. doi:10.1097/IAE.000000000000215129642238
   PubMed Web of Science ®Google Scholar
• Garces F, Jiang K, Molday LL, et al. Correlating the expression and functional activity of ABCA4 disease variants with the phenotype of patients with Stargardt disease. Invest Ophthalmol Vis Sci. 2018;59(6):2305–2315. doi:10.1167/iovs.17-2336429847635
   PubMed Web of Science ®Google Scholar
• Burke TR, Fishman GA, Zernant J, et al. Retinal phenotypes in patients homozygous for the G1961E mutation in the ABCA4 gene. Invest Ophthalmol Vis Sci. 2012;53(8):4458–4467. doi:10.1167/iovs.11-916622661473
   PubMed Web of Science ®Google Scholar
• Young AI. Solving the missing heritability problem. PLoS Genet. 2019;15(6):e1008222. doi:10.1371/journal.pgen.100822231233496
   PubMed Web of Science ®Google Scholar
• Bauwens M, Garanto A, Sangermano R, et al. ABCA4-associated disease as a model for missing heritability in autosomal recessive disorders: novel noncoding splice, cis-regulatory, structural, and recurrent hypomorphic variants. Genet Med. 2019;21(8):1761–1771. doi:10.1038/s41436-018-0420-y30670881
   PubMed Web of Science ®Google Scholar
• Bauwens M, De Zaeytijd J, Weisschuh N, et al. An augmented ABCA4 screen targeting noncoding regions reveals a deep intronic founder variant in Belgian Stargardt patients. Hum Mutat. 2015;36(1):39–42. doi:10.1002/humu.2015.36.issue-125346251
   PubMed Web of Science ®Google Scholar
• Zernant J, Lee W, Collison FT, et al. Frequent hypomorphic alleles account for a significant fraction of ABCA4 disease and distinguish it from age-related macular degeneration. J Med Genet. 2017;54(6):404–412. doi:10.1136/jmedgenet-2017-10454028446513
   PubMed Web of Science ®Google Scholar
• Sangermano R, Garanto A, Khan M, et al. Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides. Genet Med. 2019;21(8):1751–1760. doi:10.1038/s41436-018-0414-930643219
   PubMed Web of Science ®Google Scholar
• Zernant J, Lee W, Nagasaki T, et al. Extremely hypomorphic and severe deep intronic variants in the ABCA4 locus result in varying Stargardt disease phenotypes. Cold Spring Harb Mol Case Stud. 2018;4:4. doi:10.1101/mcs.a002733
   Web of Science ®Google Scholar
• Braun TA, Mullins RF, Wagner AH, et al. Non-exomic and synonymous variants in ABCA4 are an important cause of Stargardt disease. Hum Mol Genet. 2013;22(25):5136–5145. doi:10.1093/hmg/ddt36723918662
   PubMed Web of Science ®Google Scholar
• Fadaie Z, Khan M, Del Pozo-Valero M, et al. Identification of splice defects due to noncanonical splice site or deep-intronic variants in ABCA4. Hum Mutat. 2019. doi:10.1002/humu.23890
   Web of Science ®Google Scholar
• September AV, Vorster AA, Ramesar RS, Greenberg LJ. Mutation spectrum and founder chromosomes for the ABCA4 gene in South African patients with Stargardt disease. Invest Ophthalmol Vis Sci. 2004;45(6):1705–1711. doi:10.1167/iovs.03-116715161829
   PubMed Web of Science ®Google Scholar
• Aguirre-Lamban J, Riveiro-Alvarez R, Garcia-Hoyos M, et al. Comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning in the ABCA4 gene. Invest Ophthalmol Vis Sci. 2010;51(5):2615–2619. doi:10.1167/iovs.09-451819959634
   PubMed Web of Science ®Google Scholar
• Jaakson K, Zernant J, Kulm M, et al. Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat. 2003;22(5):395–403. doi:10.1002/humu.v22:514517951
   PubMed Web of Science ®Google Scholar
• Xiang Q, Cao Y, Xu H, et al. Identification of novel pathogenic ABCA4 variants in a Han Chinese family with Stargardt disease. Biosci Rep. 2019;39:1. doi:10.1042/BSR20180872
   Web of Science ®Google Scholar
• Zhang X, Ge X, Shi W, et al. Molecular diagnosis of putative Stargardt disease by capture next generation sequencing. PLoS One. 2014;9(4):e95528. doi:10.1371/journal.pone.009552824763286
   PubMed Web of Science ®Google Scholar
• Xin W, Xiao X, Li S, Jia X, Guo X, Zhang Q. Identification of genetic defects in 33 probands with Stargardt disease by WES-based bioinformatics gene panel analysis. PLoS One. 2015;10(7):e0132635. doi:10.1371/journal.pone.013263526161775
   PubMed Web of Science ®Google Scholar
• Zernant J, Xie YA, Ayuso C, et al. Analysis of the ABCA4 genomic locus in Stargardt disease. Hum Mol Genet. 2014;23(25):6797–6806. doi:10.1093/hmg/ddu39625082829
   PubMed Web of Science ®Google Scholar
• Burke TR, Tsang SH. Allelic and phenotypic heterogeneity in ABCA4 mutations. Ophthalmic Genet. 2011;32(3):165–174. doi:10.3109/13816810.2011.56539721510770
   PubMed Web of Science ®Google Scholar
• Fishman GA. Fundus flavimaculatus. A clinical classification. Arch Ophthalmol. 1976;94(12):2061–2067. doi:10.1001/archopht.1976.03910040721003999551
   PubMedGoogle Scholar
• Lois N, Holder GE, Bunce C, Fitzke FW, Bird AC. Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus. Arch Ophthalmol. 2001;119(3):359–369. doi:10.1001/archopht.119.3.35911231769
   PubMedGoogle Scholar
• Fujinami K, Lois N, Mukherjee R, et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci. 2013;54(13):8181–8190. doi:10.1167/iovs.13-1210424265018
   PubMed Web of Science ®Google Scholar
• Fujinami K, Zernant J, Chana RK, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology. 2015;122(2):326–334. doi:10.1016/j.ophtha.2014.08.01225312043
   PubMed Web of Science ®Google Scholar
• Collison FT, Fishman GA. Visual acuity in patients with Stargardt disease after age 40. Retina. 2018;38(12):2387–2394. doi:10.1097/IAE.000000000000190329068916
   PubMed Web of Science ®Google Scholar
• Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology. 2003;110(6):1151–1158. doi:10.1016/S0161-6420(03)00333-612799240
   PubMed Web of Science ®Google Scholar
• Kong X, Strauss RW, Cideciyan AV, et al. Visual acuity change over 12 months in the prospective progression of atrophy secondary to stargardt disease (ProgStar) study: progStar report number 6. Ophthalmology. 2017;124(11):1640–1651. doi:10.1016/j.ophtha.2017.04.02628549516
   PubMed Web of Science ®Google Scholar
• Kong X, Fujinami K, Strauss RW, et al. Visual acuity change over 24 months and its association with foveal phenotype and genotype in individuals with Stargardt disease: progStar study report no. 10. JAMA Ophthalmol. 2018;136(8):920–928. doi:10.1001/jamaophthalmol.2018.219829902293
   PubMed Web of Science ®Google Scholar
• Jayasundera T, Rhoades W, Branham K, Niziol LM, Musch DC, Heckenlively JR. Peripapillary dark choroid ring as a helpful diagnostic sign in advanced stargardt disease. Am J Ophthalmol. 2010;149(4):656–660 e652. doi:10.1016/j.ajo.2009.11.00520138608
   PubMed Web of Science ®Google Scholar
• Giani A, Pellegrini M, Carini E, Peroglio Deiro A, Bottoni F, Staurenghi G. The dark atrophy with indocyanine green angiography in Stargardt disease. Invest Ophthalmol Vis Sci. 2012;53(7):3999–4004. doi:10.1167/iovs.11-925822589445
   PubMed Web of Science ®Google Scholar
• Ervin AM, Strauss RW, Ahmed MI, et al. A workshop on measuring the progression of atrophy secondary to Stargardt disease in the ProgStar studies: findings and lessons learned. Transl Vis Sci Technol. 2019;8(2):16. doi:10.1167/tvst.8.2.16
   Web of Science ®Google Scholar
• Strauss RW, Munoz B, Ho A, et al. Progression of Stargardt disease as determined by fundus autofluorescence in the retrospective progression of Stargardt disease study (ProgStar report no. 9). JAMA Ophthalmol. 2017;135(11):1232–1241. doi:10.1001/jamaophthalmol.2017.415229049437
   PubMed Web of Science ®Google Scholar
• Burke TR, Duncker T, Woods RL, et al. Quantitative fundus autofluorescence in recessive Stargardt disease. Invest Ophthalmol Vis Sci. 2014;55(5):2841–2852. doi:10.1167/iovs.13-1362424677105
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Swider M, Aleman TS, et al. ABCA4-associated retinal degenerations spare structure and function of the human parapapillary retina. Invest Ophthalmol Vis Sci. 2005;46(12):4739–4746. doi:10.1167/iovs.05-080516303974
   PubMed Web of Science ®Google Scholar
• Burke TR, Rhee DW, Smith RT, et al. Quantification of peripapillary sparing and macular involvement in Stargardt disease (STGD1). Invest Ophthalmol Vis Sci. 2011;52(11):8006–8015. doi:10.1167/iovs.11-769321873672
   PubMed Web of Science ®Google Scholar
• Greenstein VC, Schuman AD, Lee W, et al. Near-infrared autofluorescence: its relationship to short-wavelength autofluorescence and optical coherence tomography in recessive stargardt disease. Invest Ophthalmol Vis Sci. 2015;56(5):3226–3234. doi:10.1167/iovs.14-1605026024107
   PubMed Web of Science ®Google Scholar
• Duncker T, Marsiglia M, Lee W, et al. Correlations among near-infrared and short-wavelength autofluorescence and spectral-domain optical coherence tomography in recessive Stargardt disease. Invest Ophthalmol Vis Sci. 2014;55(12):8134–8143. doi:10.1167/iovs.14-1484825342616
   PubMed Web of Science ®Google Scholar
• Gomes NL, Greenstein VC, Carlson JN, et al. A comparison of fundus autofluorescence and retinal structure in patients with Stargardt disease. Invest Ophthalmol Vis Sci. 2009;50(8):3953–3959. doi:10.1167/iovs.08-265719324865
   PubMed Web of Science ®Google Scholar
• Kuehlewein L, Hariri AH, Ho A, et al. Comparison of manual and semiautomated fundus autofluorescence analysis of macular atrophy in Stargardt disease phenotype. Retina. 2016;36(6):1216–1221. doi:10.1097/IAE.000000000000087026583307
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Duncker T, Schuerch K, Paavo M, de Carvalho JRL Jr. Lessons learned from quantitative fundus autofluorescence. Prog Retin Eye Res. 2019;100774. doi:10.1016/j.preteyeres.2019.10077431472235
   PubMed Web of Science ®Google Scholar
• Sauer L, Andersen KM, Li B, Gensure RH, Hammer M, Bernstein PS. Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) of macular pigment. Invest Ophthalmol Vis Sci. 2018;59(7):3094–3103. doi:10.1167/iovs.18-2388630025128
   PubMed Web of Science ®Google Scholar
• Dysli C, Wolf S, Hatz K, Zinkernagel MS. Fluorescence lifetime imaging in Stargardt disease: potential marker for disease progression. Invest Ophthalmol Vis Sci. 2016;57(3):832–841. doi:10.1167/iovs.15-1803326934141
   PubMed Web of Science ®Google Scholar
• Testa F, Rossi S, Sodi A, et al. Correlation between photoreceptor layer integrity and visual function in patients with Stargardt disease: implications for gene therapy. Invest Ophthalmol Vis Sci. 2012;53(8):4409–4415. doi:10.1167/iovs.11-820122661472
   PubMed Web of Science ®Google Scholar
• Berisha F, Feke GT, Aliyeva S, Hirai K, Pfeiffer N, Hirose T. Evaluation of macular abnormalities in Stargardt’s disease using optical coherence tomography and scanning laser ophthalmoscope microperimetry. Graefes Arch Clin Exp Ophthalmol. 2009;247(3):303–309. doi:10.1007/s00417-008-0963-818941768
   PubMed Web of Science ®Google Scholar
• Cai CX, Light JG, Handa JT. Quantifying the rate of ellipsoid zone loss in Stargardt disease. Am J Ophthalmol. 2018;186:1–9. doi:10.1016/j.ajo.2017.10.03229126757
   PubMed Web of Science ®Google Scholar
• Sodi A, Mucciolo DP, Cipollini F, et al. En face OCT in Stargardt disease. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1669–1679. doi:10.1007/s00417-015-3254-126743751
   PubMed Web of Science ®Google Scholar
• Tanna P, Georgiou M, Strauss RW, et al. Cross-sectional and longitudinal assessment of the ellipsoid zone in childhood-onset Stargardt disease. Transl Vis Sci Technol. 2019;8(2):1. doi:10.1167/tvst.8.2.1
   Web of Science ®Google Scholar
• Battaglia Parodi M, Munk MR, Iacono P, Bandello F. Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease. Br J Ophthalmol. 2015;99(9):1268–1270. doi:10.1136/bjophthalmol-2014-30578325740804
   PubMed Web of Science ®Google Scholar
• Vural E, Acar U, Sevinc MK, et al. Choroidal thickness in patients with Stargardt disease. Retina. 2018;38(3):614–619. doi:10.1097/IAE.000000000000155728198784
   PubMed Web of Science ®Google Scholar
• Adhi M, Read SP, Ferrara D, Weber M, Duker JS, Waheed NK. Morphology and vascular layers of the choroid in Stargardt disease analyzed using spectral-domain optical coherence tomography. Am J Ophthalmol. 2015;160(6):1276–1284 e1271. doi:10.1016/j.ajo.2015.08.02526314663
   PubMed Web of Science ®Google Scholar
• Nunes RP, Rosa PR, Giani A, et al. Choroidal thickness in eyes with central geographic atrophy secondary to Stargardt disease and age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):814–822.26431296
   PubMed Web of Science ®Google Scholar
• Ratra D, Jaishankar D, Sachidanandam R, Yusufali H, Ratra V. Swept-source optical coherence tomography study of choroidal morphology in Stargardt disease. Oman J Ophthalmol. 2018;11(2):150–157. doi:10.4103/ojo.OJO_21_201729930450
   PubMedGoogle Scholar
• Ratra D, Tan R, Jaishankar D, et al. Choroidal structural changes and vascularity index in Stargardt disease on swept source optical coherence tomography. Retina. 2018;38(12):2395–2400. doi:10.1097/IAE.000000000000187929016459
   PubMed Web of Science ®Google Scholar
• Arrigo A, Grazioli A, Romano F, et al. Choroidal patterns in Stargardt disease: correlations with visual acuity and disease progression. J Clin Med. 2019;8(9). doi:10.3390/jcm8091388.
   Web of Science ®Google Scholar
• Muller PL, Pfau M, Moller PT, et al. Choroidal flow signal in late-onset stargardt disease and age-related macular degeneration: an OCT-angiography study. Invest Ophthalmol Vis Sci. 2018;59(4):AMD122–AMD131. doi:10.1167/iovs.18-2381930140905
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Acquistapace A, Oldani M, et al. Dark atrophy: an optical coherence tomography angiography study. Ophthalmology. 2016;123(9):1879–1886. doi:10.1016/j.ophtha.2016.05.04127448830
   PubMed Web of Science ®Google Scholar
• Nassisi M, Baghdasaryan E, Borrelli E, Ip M, Sadda SR. Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression. PLoS One. 2019;14(2):e0212563. doi:10.1371/journal.pone.021256330794627
   PubMed Web of Science ®Google Scholar
• Thulliez M, Zhang Q, Shi Y, et al. Correlations between choriocapillaris flow deficits around geographic atrophy and enlargement rates based on swept-source OCT imaging. Ophthalmol Retina. 2019;3(6):478–488. doi:10.1016/j.oret.2019.01.02431174669
   PubMedGoogle Scholar
• Schonbach EM, Wolfson Y, Strauss RW, et al. macular sensitivity measured with microperimetry in Stargardt disease in the progression of atrophy secondary to Stargardt disease (ProgStar) study: report no. 7. JAMA Ophthalmol. 2017;135(7):696–703. doi:10.1001/jamaophthalmol.2017.116228542693
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Swider M, Aleman TS, et al. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest Ophthalmol Vis Sci. 2012;53(2):841–852. doi:10.1167/iovs.11-841522247458
   PubMed Web of Science ®Google Scholar
• Verdina T, Tsang SH, Greenstein VC, et al. Functional analysis of retinal flecks in Stargardt disease. J Clin Exp Ophthalmol. 2012;3.
   Google Scholar
• Parodi MB, Triolo G, Morales M, et al. Mp1 and maia fundus perimetry in healthy subjects and patients affected by retinal dystrophies. Retina. 2015;35(8):1662–1669. doi:10.1097/IAE.000000000000050426214316
   PubMed Web of Science ®Google Scholar
• Schonbach EM, Ibrahim MA, Strauss RW, et al. Fixation location and stability using the MP-1 microperimeter in Stargardt disease: progStar report no. 3. Ophthalmol Retina. 2017;1(1):68–76. doi:10.1016/j.oret.2016.08.00931047397
   PubMedGoogle Scholar
• Verdina T, Giacomelli G, Sodi A, et al. Biofeedback rehabilitation of eccentric fixation in patients with Stargardt disease. Eur J Ophthalmol. 2013;23(5):723–731. doi:10.5301/ejo.500029123640508
   PubMed Web of Science ®Google Scholar
• Hussain RM, Gregori NZ, Ciulla TA, Lam BL. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin Pharmacother. 2018;19(5):471–481. doi:10.1080/14656566.2018.144806029542350
   PubMed Web of Science ®Google Scholar
• Kubota R, Al-Fayoumi S, Mallikaarjun S, Patil S, Bavik C, Chandler JW. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina. 2014;34(3):603–609. doi:10.1097/01.iae.0000434565.80060.f824056528
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Dugel PU, Holz FG, et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2018;125(10):1556–1567. doi:10.1016/j.ophtha.2018.03.05929716784
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of emixustat in Stargardt disease (SeaSTAR); 2019 Available from: https://clinicaltrials.gov/ct2/show/NCT03772665. Accessed 916, 2019.
   Google Scholar
• Ma L, Kaufman Y, Zhang J, Washington I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011;286(10):7966–7974. doi:10.1074/jbc.M110.17865721156790
   PubMed Web of Science ®Google Scholar
• Phase 2 tolerability and effects of ALK-001 on Stargardt disease (TEASE). Available from: https://clinicaltrials.gov/ct2/show/NCT02402660.
   Google Scholar
• Radu RA, Mata NL, Nusinowitz S, Liu X, PA S, Travis GH. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt’s macular degeneration. Proc Natl Acad Sci U S A. 2003;100(8):4742–4747. doi:10.1073/pnas.073785510012671074
   PubMed Web of Science ®Google Scholar
• Dobri N, Qin Q, Kong J, et al. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Invest Ophthalmol Vis Sci. 2013;54(1):85–95. doi:10.1167/iovs.12-1005023211825
   PubMed Web of Science ®Google Scholar
• Zhou J, Kim SR, Westlund BS, Sparrow JR. Complement activation by bisretinoid constituents of RPE lipofuscin. Invest Ophthalmol Vis Sci. 2009;50(3):1392–1399. doi:10.1167/iovs.08-286819029031
   PubMed Web of Science ®Google Scholar
• Radu RA, Hu J, Yuan Q, et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem. 2011;286(21):18593–18601. doi:10.1074/jbc.M110.19186621464132
   PubMed Web of Science ®Google Scholar
• Lenis TL, Sarfare S, Jiang Z, Lloyd MB, Bok D, Radu RA. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease. Proc Natl Acad Sci U S A. 2017;114(15):3987–3992. doi:10.1073/pnas.162029911428348233
   PubMed Web of Science ®Google Scholar
• Han Z, Conley SM, Naash MI. Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol. 2014;801:719–724.24664763
   PubMed Web of Science ®Google Scholar
• Auricchio A, Trapani I, Allikmets R. Gene therapy of ABCA4-associated diseases. Cold Spring Harb Perspect Med. 2015;5(5):a017301. doi:10.1101/cshperspect.a01730125573774
   PubMed Web of Science ®Google Scholar
• Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 2008;15(19):1311–1320. doi:10.1038/gt.2008.7818463687
   PubMed Web of Science ®Google Scholar
• Binley K, Widdowson P, Loader J, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci. 2013;54(6):4061–4071. doi:10.1167/iovs.13-1187123620430
   PubMed Web of Science ®Google Scholar
• Phase I/II Study of SAR422459 in patients with Stargardt’s macular degeneration. Available from: https://clinicaltrials.gov/ct2/show/NCT01367444.
   Google Scholar
• Lund RD, Wang S, Klimanskaya I, et al. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 2006;8(3):189–199. doi:10.1089/clo.2006.8.18917009895
   PubMedGoogle Scholar
• Klein R, Lewis RA, Meyers SM, Myers FL. Subretinal neovascularization associated with fundus flavimaculatus. Arch Ophthalmol. 1978;96(11):2054–2057. doi:10.1001/archopht.1978.03910060442009718494
   PubMedGoogle Scholar
• Valmaggia C, Niederberger H, Helbig H. Photodynamic therapy for choroidal neovascularization in fundus flavimaculatus. Retina. 2002;22(1):111–113. doi:10.1097/00006982-200202000-0002211884891
   PubMed Web of Science ®Google Scholar
• Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and safety of ranibizumab 0.5 mg for the treatment of macular edema resulting from uncommon causes: twelve-month findings from PROMETHEUS. Ophthalmology. 2018;125(6):850–862. doi:10.1016/j.ophtha.2017.12.00229371007
   PubMed Web of Science ®Google Scholar